低剂量中度低分离放射治疗无节奏非霍奇金淋巴瘤:一个多中心,单臂,第二阶段试验
Xin-Yue Wang1, Xi-Mei Zhang2, Liang Wang3
1Department of Radiation Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Department of Radiation Oncology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
The Lancet. Haematology
|May 5, 2025
概括
低剂量放射治疗方案12 Gy分为四部分,在患有无节奏非霍奇金淋巴瘤的患者中显示出高完全响应率和有利的安全概况.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 血液学 血液学 血液学
背景情况:
- 无节奏非霍奇金淋巴瘤 (iNHL) 的放射治疗旨在平衡治疗有效性与降低毒性.
- 不断发展的放射治疗技术旨在优化剂量以获得最终治疗.
研究的目的:
- 评估一个低分离放射治疗方案的安全性和有效性,为NHL提供12 Gy的四个分量.
- 评估与这种低剂量疗法相关的完整反应率和不良事件.
主要方法:
- 进行了一项多中心,单臂,第二阶段试验,涉及新诊断或复发的I-IV期惰性非霍奇金淋巴瘤患者.
- 患者接受了12 Gy的参与部位放射治疗,分为四部分.
- 主要终点是放射治疗后6个月的完全响应率.
主要成果:
- 该研究招募了71名患者,73个目标部位;中位数随访时间为19个月.
- 观察到6个月完整响应率为95% (73个地点中的69个).
- 最常见的急性不良事件是1级淋巴缺血 (28%) 和1级恶心 (19%);3级淋巴缺血发生在11%的患者中,没有与治疗相关的死亡.
结论:
- 12Gy四个部分的放射治疗方案是一种安全有效的局部治疗选择,用于无节奏的非霍奇金淋巴瘤.
- 需要进一步的研究来证实这种低分数策略的有效性,特别是考虑到试验的追溯注册.
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...